David A. Braun, MD, PhD

David A. Braun, MD, PhD, is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center

Articles

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

March 8th 2024

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

March 1st 2024

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

March 1st 2024

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

February 23rd 2024

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

First-Line Treatments for Advanced Clear Cell RCC

February 23rd 2024

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC

November 10th 2023

David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.

Dr Braun on Frontline Nivolumab Monotherapy Followed by Salvage Nivolumab/Ipilimumab in RCC

April 10th 2023

David A. Braun, MD, PhD, discusses the rationale for evaluating frontline nivolumab and salvage nivolumab plus ipilimumab in patients with advanced renal cell carcinoma in the phase 2 HCRN GU16-260 trial.

Dr. Braun on the Role of SLAMF7+ CD8+ T-cells in Nivolumab-Resistant RCC

March 1st 2023

David A. Braun, MD, PhD, discusses the enrichment of SLAMF7-positive, CD8-positive T-cells and their role on nivolumab resistance in clear cell and non–clear cell renal cell carcinoma.

Dr. Braun on Unanswered Questions With PD-1 Blockade in Advanced RCC

July 28th 2020

David A. Braun, MD, PhD, discusses unanswered questions regarding the utility of PD-1 blockade in advanced renal cell carcinoma.

Dr. Braun on Frontline Immunotherapy in Advanced RCC

February 7th 2020

David A. Braun, MD, PhD, physician at Dana-Farber Cancer Institute and instructor of medicine at Harvard Medical School, discusses the use of immunotherapy in the frontline treatment of patients with advanced renal cell carcinoma (RCC).

Dr. Braun on Evolution of Immunotherapy in Advanced Renal Cell Carcinoma

January 30th 2020

David A. Braun, MD, PhD, discusses the evolution of immunotherapy in advanced renal cell carcinoma.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 4th 2019

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.